Core Viewpoint - Certara, Inc. will release its financial results for Q2 2025 on August 6, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Investor Information - Investors interested in the conference call must register online, with a recommendation to do so at least one day in advance [1]. - A live and archived webcast of the conference call will be available on the "Investors" section of Certara's website [2]. Contact Information - Investor Relations contact is David Deuchler from Gilmartin Group [4]. - Media contact is Alyssa Horowitz [4].

Simulations Plus' ( SLP ) share price plummeted after the company reported preliminary Q3 FY25 results that fell well short of expectations. While soft biopharma market conditions and Simulations Plus' relatively large services business mean that current weakness is not surprising, the companyRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adju ...

Core Insights - Charles River Laboratories International, Inc. (CRL) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.34, a 3.1% increase year over year, exceeding the Zacks Consensus Estimate by 13.6% [1] - Total revenues for the first quarter reached $984.2 million, surpassing the Zacks Consensus Estimate by 5.2%, but reflecting a 2.4% decline from the previous year [2] - The company raised its 2025 guidance, indicating improved net bookings in the Discovery and Safety Assessment (DSA) segment [12] Financial Performance - The gross profit for the quarter was $317.7 million, down 7.9% from the prior year, with a gross margin of 32.3%, contracting 181 basis points year over year [7] - Selling, general & administrative expenses decreased by 4.6% year over year to $177.8 million, while adjusted operating profit fell 11.7% to $139.9 million [7] - The company exited the first quarter with cash and cash equivalents of $229.4 million, an increase from $194.6 million at the end of the previous quarter [8] Segment Performance - Research Models and Services (RMS) revenues totaled $213.1 million, down 3.5% year over year, primarily due to timing of shipments in China and lower revenues in the Cell Solutions business [4] - Discovery and Safety Assessment (DSA) revenues amounted to $592.6 million, a decline of 2.1% year over year, attributed to lower revenues for discovery services [5] - Manufacturing Solutions revenues were $178.5 million, down 3.6% year over year, mainly due to declines in CDMO and Biologics Testing businesses [6] Shareholder Returns - During the first quarter, the company repurchased 2.1 million shares for a total of $350 million, with a remaining authorization of $549.3 million under its $1 billion stock repurchase program [9] 2025 Guidance - For 2025, CRL expects total revenues to decline in the range of 5.5%-3.5%, an improvement from the earlier estimate of 4.5%-7% [10] - Adjusted EPS for 2025 is projected to be in the range of $9.30-$9.80, up from the previous range of $9.10-$9.60 [11]

Reiterates Full-Year 2025 Guidance Arsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 mill ...